We hypothesize that corticotropin or adrenocorticotrophic hormone (ACTH), administered as
Acthar Gel® (MANUFACTURER NAME) is effective in the control of clinical disease activity as a
pulse therapy for relapsing-remitting MS when added to standard treatment with
beta-interferon.
We wish to determine whether ACTH, when administered as clustered monthly intramuscular
injections (monthly pulse therapy) as add-on to beta-interferons, may be a safe and effective
alternative to monthly pulse therapy with MP. In addition, we hypothesize that pulse therapy
with ACTH alters immune function to favor a regulatory, rather than a pro-inflammatory T cell
environment.